GSK touts topline win for PD-1 in head-to-head with Keytru­da — while steer­ing next big check­point drug in­to PhI­II

GSK is claim­ing a win for what it calls the largest head-to-head tri­al pit­ting a PD-1 against Mer­ck’s best-sell­ing Keytru­da in a type of lung can­cer, as its Jem­per­li met the pri­ma­ry end­point of ob­jec­tive re­sponse rate.

In a sep­a­rate pos­i­tive move, GSK says it’s mov­ing both arms of the COSTAR Lung tri­al in­to Phase III to test Jem­per­li as well as the TIM-3 in­hibitor cobolimab.

He­s­ham Ab­dul­lah, GSK’s glob­al head of on­col­o­gy de­vel­op­ment, said in a state­ment that the two tri­als “sup­port the am­bi­tion for dostar­limab to be­come the back­bone of our on­go­ing im­muno-on­col­o­gy-based re­search and de­vel­op­ment pro­gramme when used alone and in com­bi­na­tion with stan­dard of care and fu­ture nov­el can­cer ther­a­pies, par­tic­u­lar­ly in pa­tients with cur­rent­ly lim­it­ed treat­ment op­tions.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER